Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes

Research output: Contribution to journalArticlepeer-review

Authors

  • Renhe Liu
  • Xiaoxuan Lyu
  • Meihui Hsu
  • Michael B Harbut
  • Catherine Vilcheze
  • Bo Cheng
  • Kehinde Ajayi
  • Baiyuan Yang
  • Yun Yang
  • Hui Guo
  • Changyou Lin
  • Fei Gan
  • Chen Wang
  • Scott G Franzblau
  • William R Jacobs Jr.
  • Eric F Johnson
  • Mike Petrassi
  • Arnab K Chatterjee
  • Feng Wang

Colleges, School and Institutes

External organisations

  • California Institute for Biomedical Research
  • Scripps Res Inst
  • Albert Einstein College of Medicine
  • University of Illinois

Abstract

Mycobacterium tuberculosis (Mtb) DprE1, an essential isomerase for the biosynthesis of the mycobacterial cell wall, is a validated target for tuberculosis (TB) drug development. Here we report the X-ray crystal structures of DprE1 and the DprE1 resistant mutant (Y314C) in complexes with TCA1 derivatives to elucidate the molecular basis of their inhibitory activities and an unconventional resistance mechanism, which enabled us to optimize the potency of the analogs. The selected lead compound showed excellent in vitro and in vivo activities, and low risk of toxicity profile except for the inhibition of CYP2C9. A crystal structure of CYP2C9 in complex with a TCA1 analog revealed the similar interaction patterns to the DprE1-TCA1 complex. Guided by the structures, an optimized molecule was generated with differential inhibitory activities against DprE1 and CYP2C9, which provides insights for development of a clinical candidate to treat TB.

Details

Original languageEnglish
Pages (from-to)13011–13015
JournalAngewandte Chemie (International Edition)
Volume56
Issue number42
Early online date15 Aug 2017
Publication statusPublished - 7 Sep 2017

Keywords

  • DprE1, CYP2C9, anti-tubercular drugs, drug-drug interactions, drug development

Sustainable Development Goals